| Literature DB >> 30090697 |
Lauren E Gascoyne1, Karen J Mullinger2, Siân E Robson2, Jyothika Kumar3, George C O'Neill2, Lena Palaniyappan4, Peter G Morris2, Elizabeth B Liddle3, Matthew J Brookes2, Peter F Liddle5.
Abstract
The healthy brain is able to maintain a stable balance between bottom-up sensory processing and top-down cognitive control. The neurotransmitter acetylcholine plays a substantial role in this. Disruption of this balance could contribute to symptoms occurring in psychosis, including subtle disruption of motor control and aberrant appropriation of salience to external stimuli; however the pathological mechanisms are poorly understood. On account of the role beta oscillations play in mediating cognitive control, investigation of beta oscillations is potentially informative about such mechanisms. Here, we used magnetoencephalography to investigate the effect of the acetylcholinesterase-inhibitor, galantamine, on beta oscillations within the sensorimotor region during both a sensorimotor task and a relevance-modulation task in healthy participants, employing a double blind randomized placebo controlled cross-over design. In the galantamine condition, we found a significant reduction in the post-movement beta rebound in the case of executed movements and also in a planned but not executed movement. In the latter case, the effect was significantly greater following task-relevant compared with irrelevant stimuli. The results suggest that the action of galantamine reduces the influence of top-down cognitive processing relative to bottom-up perceptual processing in a manner resembling changes previously reported in schizophrenia.Entities:
Keywords: Acetylcholine; Beta oscillations; Magnetoencephalography; PMBR; Schizophrenia
Mesh:
Substances:
Year: 2018 PMID: 30090697 PMCID: PMC6078055 DOI: 10.1016/j.nicl.2018.07.019
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Fig. 1Visuomotor task results: A) Beamformer source reconstructions, at 78 AAL regions, of cortical beta (13–30 Hz) amplitude changes for the motor task. All images contrast an active window during movement (2–3 s) and a comparison window during the rebound (3–4 s). B) Time frequency spectrograms (baseline corrected) for left sensory AAL region in the galantamine (top) and placebo (middle) conditions. The lower panel shows the difference between these for visualisation. C) Hilbert envelope time courses in the beta band, baseline uncorrected. The red time course shows the galantamine condition, the blue time course shows the placebo condition. Note that in both B and C a marked reduction in the amplitude of the beta rebound with galantamine is observed.
Fig. 2Relevance Modulation Task Results A) Time frequency spectrograms for averaged relevant, irrelevant and difference spectrograms in the galantamine and placebo conditions for the beta band. B) Amplitude envelope time courses (without baseline subtraction) for the beta band. The red time course shows the relevant condition, the blue time course shows the irrelevant condition.
| Symptom | Drug day (N) | Placebo day (N) |
|---|---|---|
| No symptoms | 23 | 36 |
| Nausea | 9 | – |
| Drowsy | 3 | 3 |
| Dizzy | 9 | – |
| Stomach pain | 2 | – |
| Lightheaded | 2 | 2 |
| Headache | 1 | 1 |
| Blurry vision | – | 1 |
| Heartburn | – | 1 |
| Overheating | 1 | – |
| Elevated heart rate | 1 | – |
| Adverse effects (vomiting, severe dizziness) | 3 | – |
| Task | Felt ‘fine’ (N) | Drug side effects (N) |
|---|---|---|
| Visuo-motor | 17 | 15 |
| Relevance Modulation | 21 | 15 |